Celgene Corporation

Celgene Corporation was a biopharmaceutical company focused on developing innovative therapies for cancer and inflammatory diseases. Established in 1986, it gained recognition for its flagship drug, Revlimid, used in treating multiple myeloma. Celgene's work involved advanced research and clinical trials to create treatments that improve patient outcomes. In 2019, Celgene was acquired by Bristol-Myers Squibb, a move that expanded Bristol-Myers’ oncology portfolio and reinforced its commitment to addressing serious medical conditions. Celgene’s legacy continues through its contributions to cancer treatment and ongoing research initiatives.